Skip to main content
Download PDF

The new useful high-resolution computed tomography finding for diagnosing fibrotic hypersensitivity pneumonitis: “hexagonal pattern”: a single-center retrospective study

BMC Pulmonary Medicine volume 22, Article number: 76 (2022) Cite this article

Abstract

Background

Centrilobular nodules, ground-glass opacity (GGO), mosaic attenuation, air trapping, and three-density pattern were reported as high-resolution computed tomography (HRCT) findings characteristic of fibrotic hypersensitivity pneumonitis (HP). However, it is often difficult to differentiate fibrotic HP from idiopathic pulmonary fibrosis (IPF). In fibrotic HP, the HRCT sometimes shows tortoiseshell-like interlobular septal thickening that extends from the subpleural lesion to the inner layers. This finding is called “hexagonal pattern,” and this study is focused on the possibility that such finding is useful for differentiating fibrotic HP from IPF.

Methods

This study included patients with multidisciplinary discussion (MDD) diagnosis of fibrotic HP or IPF undergoing surgical lung biopsy between January 2015 and December 2017 in Kanagawa Cardiovascular and Respiratory Center. Two radiologists have evaluated the HRCT findings without clinical and pathological information.

Results

A total of 23 patients were diagnosed with fibrotic HP by MDD and 48 with IPF. Extensive GGO, centrilobular nodules, and hexagonal pattern were more frequent findings in fibrotic HP than in IPF. No significant difference was observed between the two groups in the presence or absence of mosaic attenuation, air trapping, or three-density pattern. In the multivariate logistic regression, the presence of extensive GGO and hexagonal pattern was associated with increased odds ratio of fibrotic HP. The sensitivity and specificity of the diagnosis of fibrotic HP in the presence of the hexagonal pattern were 69.6% and 87.5%, respectively.

Conclusion

Hexagonal pattern is a useful finding for differentiating fibrotic HP from IPF.

Peer Review reports

Background

Two guidelines have recently been proposed for diagnosing hypersensitivity pneumonitis (HP), which state that lung biopsy is not necessary for the diagnosis of HP if antigen exposure, typical high-resolution computed tomography (HRCT) findings, and bronchoalveolar lavage (BAL) lymphocytosis have been identified [1, 2]. However, in fibrotic HP, the antigen is often unknown, and most cases need lung biopsy. In addition, specimens collected via transbronchial forceps biopsies or transbronchial lung cryobiopsy (TBLC) are insufficient in size for the diagnosis of fibrotic HP, and surgical lung biopsy (SLB) is often required. Conversely, SLB is often not feasible due to the patient’s background or facility issues. Therefore, HRCT imaging plays a significant role in the diagnosis of fibrotic HP.

HRCT findings characteristic of fibrotic HP include centrilobular nodules, ground-glass opacity (GGO), mosaic attenuation, air trapping, and three-density pattern in previous reports [1,2,3,4,5,6,7,8]. These findings are not specific to fibrotic HP only, and many cases of fibrotic HP were found without typical HRCT findings.

Approximately half of chronic HP has been reported to have histological usual interstitial pneumonia (UIP)-like pattern and extensive fibrosis with poor prognosis [9]. Fibrotic HP with UIP pattern is common and often difficult to distinguish from idiopathic pulmonary fibrosis (IPF) in clinical practice. However, differentiating between fibrotic HP and IPF is important as they differ in their treatment strategies.

In fibrotic HP, the HRCT sometimes shows tortoiseshell-like interlobular septal thickening that extends from the subpleural region to the inner layers. This finding is called “hexagonal pattern,” and this study focused on the possibility that such finding is useful for differentiating fibrotic HP from IPF (Fig. 1).

Fig. 1
figure 1

Hexagonal pattern in the HRCT. a, b Hexagonal pattern is an interlobular septal thickening expanding from the subpleural region to two or more inner layers of the secondary pulmonary lobules. c When there is subpleural collapse such that the structure of the secondary pulmonary lobules is no longer recognizable, hexagonal pattern was defined as interlobular septal thickening that expands to two or more inner layers of the secondary pulmonary lobules from the collapsed area

Full size image

Methods

Patients

This study included patients with multidisciplinary discussion (MDD) diagnosis of fibrotic HP or IPF undergoing SLB between January 2015 and December 2017 in Kanagawa Cardiovascular and Respiratory Center. The diagnosis of IPF and fibrotic HP was based on consensus using previously reported criteria [5, 10,11,12]. The exclusion criteria of this study were as follows: (1) patients that had collagen vascular diseases or pulmonary alveolar proteinosis, (2) patients that met the interstitial pneumonia with autoimmune features diagnostic criteria [13], (3) patients that developed collagen vascular disease following MDD, and (4) patients that have already been given medication, including steroids or immunosuppressant, before biopsy.

The patient’s baseline characteristics, including age, gender, smoking status, peripheral blood counts, blood biochemistry, pulmonary function tests, and BAL findings at the time of MDD, were retrospectively obtained from the medical records. This study was performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Kanagawa Cardiovascular and Respiratory Center (permission number: KCRC-20-0023, permission date: August 18, 2020). The opt-out consent was adopted for patient enrollment in this study.

The definition of hexagonal pattern

Hexagonal pattern is defined as an interlobular septal thickening expanding from the subpleural region to two or more inner layers of secondary pulmonary lobules (Fig. 1a, b). When there is subpleural collapse such that the structure of secondary pulmonary lobules is no longer recognizable, hexagonal pattern was defined as interlobular septal thickening that expands to two or more inner layers of secondary pulmonary lobules from the collapsed area (Fig. 1c).

Figure 2 presents the pathological specimen obtained via SLB of a patient with hexagonal pattern. Perilobular fibrosis and bridging fibrosis connecting the fibrosis in the centrilobular area and the fibrosis in the perilobular area were observed in this specimen. In this case, the hexagonal pattern observed in the HRCT corresponded to that of perilobular fibrosis.

Fig. 2
figure 2

The pathological specimen of the patient with hexagonal pattern in HRCT. a, b The HRCT shows interlobular septal thickening expanding from the subpleural region to two or more inner layers of the secondary pulmonary lobules. c, d The specimen of right S9 obtained via surgical lung biopsy. Perilobular fibrosis and bridging fibrosis connecting the fibrosis in the centrilobular area and the fibrosis in the perilobular area were observed. The arrows indicate bridging fibrosis. In this case, the hexagonal pattern observed in the HRCT corresponded to perilobular fibrosis. ILS, interlobular septum; V, vein; A, artery; RB, respiratory bronchiole; HE, hematoxylin and eosin; EvG, Elastica van Gieson

Full size image

Radiological evaluation

The radiological data were reviewed by two chest radiologists (T.I. and D.F.). HRCT images were independently evaluated, and the final findings were agreed upon by consensus between the two radiologists. The radiologists knew that only patients with fibrotic HP or IPF were included in the study, but they evaluated the HRCT findings without clinical and pathological information. The two radiologists have retrospectively evaluated the shadow distribution and the following findings: hexagonal pattern, extensive GGO, centrilobular nodules, mosaic attenuation, air trapping, three-density pattern, reticulation, traction bronchiectasis, honeycombing, consolidation, emphysema, cyst, and pleuroparenchymal fibroelastosis. The HRCT findings were interpreted based on the recommendations of the Nomenclature Committee of the Fleischner Society [14]. In this study, mosaic attenuation, air trapping, and three-density pattern were defined as being present when they were found in three or more lobules bilaterally. Before the radiological evaluation, two teacher images were shown to confirm the definition of hexagonal pattern. The classification of cases as UIP, probable UIP, indeterminate for UIP, or alternative diagnosis using the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) guidelines for diagnosing IPF was performed retrospectively [12].

Statistical analysis

Continuous variables are expressed as median values. The Mann–Whitney U test, chi-squared test, or Fisher’s exact probability test was employed, as appropriate, for between-group comparisons. The interobserver variation between two radiologists for the diagnosis of fibrotic HP or IPF was analyzed using κ statistic. A κ coefficient equal to or less than 0.20 indicated poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement; and 0.81–1.00, excellent agreement. Univariate and multivariate logistic analyses were employed to identify the useful HRCT findings for distinguishing fibrotic HP from IPF. A p-value of < 0.05 was considered to be significant. All statistical analyses have been conducted using the Statistical Package for the Social Sciences software version 24.0 (IBM; Armonk, NY, USA).

Results

Patient characteristics

During the study period, 216 patients diagnosed with interstitial lung disease underwent SLB at our hospital. A total of 28 patients were diagnosed with fibrotic HP by MDD at the time of SLB and 51 with IPF. Among the fibrotic HP patients, one had pulmonary alveolar proteinosis, and one had Sjögren’s syndrome. Among the IPF patients, one met the diagnosis criteria of interstitial pneumonia with autoimmune features. One patient each with IPF and fibrotic HP received steroids prior to SLB. One patient with IPF developed rheumatoid arthritis after biopsy. Excluding cases that met the exclusion criteria, 23 cases of fibrotic HP and 48 cases of IPF were considered in this study (Fig. 3). The ATS/JRS/ALAT Clinical Practice Guideline of the diagnosis of HP was published in 2020 [1], but the diagnosis in this study was made before this guideline was reported. The fibrotic HP diagnosis was again reviewed according to this guideline, and all cases of fibrotic HP diagnosed by MDD were found to meet the criteria for definite or high-confidence HP.

Fig. 3
figure 3

Patient flow diagram. MDD, multidisciplinary discussion; SLB, surgical lung biopsy; HP, hypersensitivity pneumonitis; IPF, idiopathic pulmonary fibrosis; IPAF, interstitial pneumonia with autoimmune features

Full size image

Table 1 presents the characteristic of the patients with fibrotic HP and IPF at the MDD. The serum Krebs von den Lungen-6 and surfactant protein-D levels were higher in fibrotic HP than in IPF patients. The percent predicted forced vital capacity (FVC), percent predicted forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and percent predicted diffusion lung capacity for carbon monoxide (DLCO) at diagnosis were not significantly different between the two groups. The lymphocyte ratio and CD4/8 ratio in BAL were significantly higher among fibrotic HP patients.

Table 1 Patient characteristics
Full size table

HRCT assessment

Interobserver agreement across the two radiologists in the HRCT findings other than pleuroparenchymal fibroelastosis was fair to good. The kappa coefficient of hexagonal pattern was 0.44, indicating moderate agreement (Table 2). Extensive GGO, centrilobular nodules, and hexagonal pattern were more frequently observed in fibrotic HP than in IPF. A significant difference in axial distribution was also found between fibrotic HP and IPF.

Table 2 HRCT findings
Full size table

Mosaic attenuation, air trapping, or three-density pattern were reported as findings suggestive of fibrotic HP [1, 2, 6, 7], but no significant difference was observed in this study (Table 2). The logistic regression for predicting fibrotic HP is presented in Table 3. In the univariate logistic regression, the presence of extensive GGO, centrilobular nodules, and hexagonal pattern was associated with increased odds ratio of fibrotic HP. Extensive GGO and hexagonal pattern were the remaining variables in multivariate logistic regression. The presence of hexagonal pattern was highly specific (87.5%) for diagnosing fibrotic HP. The sensitivity for fibrotic HP diagnosis when hexagonal pattern was present was 69.6%. The positive predictive value of hexagonal pattern was 72.7% for fibrotic HP diagnosis.

Table 3 Logistic regression predicting fibrotic HP
Full size table

Discussion

This study has demonstrated that hexagonal pattern can be a useful finding for differentiating fibrotic HP from IPF.

HP is a diffuse interstitial pneumonia caused by immune response to inhaled antigen. Inhaled substances are usually most likely deposited at the level of the respiratory bronchioles, and small particles of 2.5 μm or less reach the alveolar region via diffusion, are phagocytosed by alveolar macrophages, and then enter the lymphatics. The distribution of lymphatic vessels in the lungs is largely divided into two routes. One lymphatic flow follows the bronchovascular bundles to the hilum in the inner layers. The other route starts at the perivenular area in the secondary lobule, runs through the interlobular septa or subpleural lymphatic vessels, and ends at the hilum [15]. In experiments using inhaled antigens, the most frequent site of granuloma formation in response to antigens is from the respiratory bronchioles to the alveolar ducts, as has been reported [16]. The deposition of inhaled substances into the respiratory bronchial habit is thought to be involved in the formation of lobular central lesions, whereas deposition by lymphatic flow is thought to be involved in the fibrosis of the lobular margins, i.e., subpleural and interlobular septal predominance.

Centrilobular nodules, extensive GGO, mosaic attenuation, air trapping, diffuse axial distribution, and upper or mid-lung predominance have been reported as useful HRCT findings for fibrotic HP diagnosis in previous reports [3, 4, 6, 8]. However, these studies differed in patient backgrounds or diagnostic methods, including with or without lung biopsy: some studies included nonfibrotic HP and fibrotic HP and other studies included other ILDs and IPF as control diseases.

The study comparing IPF with bird-related chronic HP that had histological UIP pattern reported that upper or mid-lung predominance and profuse micronodules were reported as key findings in chronic HP diagnosis [8]. The usefulness of the three-density pattern for differentiating fibrotic HP from IPF was reported, but in this study, not all patients underwent SLB [7]. The present study did not include cases with three-density pattern, and no significant difference in the presence of mosaic attenuation was observed between the two groups. This may be because this study included only those cases that required SLB as clinical information and radiological findings did not lead to the diagnosis. This suggests that the hexagonal pattern may be useful for differentiating fibrotic HP from IPF, even without a three-density pattern.

Fibrosis of HP manifesting as irregular reticulation is often visible on HRCT, which appears as thickened interlobular septa [1, 17, 18]. This finding usually correlates with the presence of fibrosis predominantly affecting the periphery of acini and the secondary lobule rather than the septa themselves. The study about HP in North India has reported that septal thickening was observed in nearly 30% of patients [19]. However, patients with IPF or other ILD with UIP pattern also often have irregular interlobular septal thickening [17].

This study proposed that not only the presence of interlobular septal thickening just below the pleura but also the extension of interlobular septal thickening to the inner layers, exhibiting a tortoiseshell-like pattern (hexagonal pattern), may be more characteristics of fibrotic HP than IPF.

In the case presented in Fig. 2, the area showing a hexagonal pattern was biopsied, and the hexagonal pattern in the HRCT was thought to correspond to perilobular fibrosis. However, in this study, SLB was not performed at selected sites with hexagonal pattern; thus, the HRCT findings and pathology in all patients enrolled have not been compared in this study. Since hexagonal pattern is a shadow that extends to the inner layers, in some cases, the shadow is found in the inner layers beyond the area that can be sampled by SLB.

Recently, the utility of TBLC has been reported in the diagnosis of diffuse lung disease [20,21,22,23]. Cryoprobe-retrieved specimens are larger than those of transbronchial forceps biopsies and less crush. TBLC tends to sample more proximal portion of the lung apart from the pleura compared with SLB. In the future, TBLC and SLB may be useful for comparing the imaging and pathology of the cases with hexagonal pattern in HRCT.

This study has several limitations. First, this was a single-center retrospective study, which may be subjected to various biases. External validation studies are warranted in the future. Second, this study included only patients who underwent SLB. Fibrotic HP and IPF, which can be diagnosed by clinical information, HRCT findings, and histological findings by transbronchial forceps biopsies or TBLC, were not included. However, the problem in clinical practice is the differentiation between IPF and fibrotic HP, which requires SLB. It is noteworthy that in this study, the hexagonal pattern was useful for differentiating between the two diseases, even in cases that the diagnosis could not be made based on clinical and imaging findings. Future studies including a cohort comprising of patients with fibrotic HP diagnosed without SLB should be conducted. Third, the interobserver agreement for hexagonal pattern was not high. However, the problem is not limited to hexagonal patterns only, but it is also seen with findings such as GGO and centrilobular nodules, which have been reported to be characteristics of fibrotic HP. Previous studies on HRCT findings in hypersensitivity pneumonitis have also shown only fair to moderate agreement among radiologists for these finding at rates comparable to this study [6, 8]. In this study, the interobserver agreement for hexagonal pattern was higher than that of GGO and centrilobular nodules. Therefore, we believe that the interobserver agreement in this study is not abnormally low, and it is simply necessary to examine more cases in the future. It is thought that a more accurate diagnosis of fibrotic HP can be made by combining multiple findings suggestive of fibrotic HP, rather than a single finding, and we hope that hexagonal pattern will be one of them. Finally, we did not examine whether the hexagonal pattern is useful in differentiating fibrotic HP from diffuse lung diseases other than IPF. In the future, we are planning to compare the HRCT findings of fibrotic HP with other diffuse lung diseases.

Conclusion

Hexagonal pattern is a useful finding for differentiating fibrotic HP from IPF. Further external validation studies should be conducted to evaluate the utility of hexagonal pattern for diagnosing fibrotic HP.

Availability of data and materials

The dataset supporting the conclusions of this article is presented within the article. The detailed clinical data is not available because of patients’ confidentiality.

Abbreviations

HRCT:

High-resolution computed tomography

HP:

Hypersensitivity pneumonitis

IPF:

Idiopathic pulmonary fibrosis

MDD:

Multidisciplinary discussion

BAL:

Bronchoalveolar lavage

TBLC:

Transbronchial lung cryobiopsy

SLB:

Surgical lung biopsy

GGO:

Ground-glass opacity

UIP:

Usual interstitial pneumonia

References

  1. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202(3):e36–69.

    Article  Google Scholar 

  2. Fernandez Perez ER, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest. 2021;160(2):e97–156.

    Article  Google Scholar 

  3. Lynch DA, Newell JD, Logan PM, King TE, Müller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995;165(4):807–11.

    Article  CAS  Google Scholar 

  4. Silva CIS, Müller NL, Lynch DA, et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008;246(1):288–97.

    Article  Google Scholar 

  5. Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196(6):690–9.

    Article  Google Scholar 

  6. Salisbury ML, Gross BH, Chughtai A, et al. Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis. Eur Respir J. 2018;52(2):1800443.

    Article  Google Scholar 

  7. Barnett J, Molyneaux PL, Rawal B, et al. Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis. Eur Respir J. 2019;54(1):1900531.

    Article  CAS  Google Scholar 

  8. Tateishi T, Johkoh T, Sakai F, et al. High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. Jpn J Radiol. 2020;38(6):524–32.

    Article  Google Scholar 

  9. Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier’s lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax. 2005;60(8):665–71.

    Article  CAS  Google Scholar 

  10. Lacasse Y, Selman M, Costabel U, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168(8):952–8.

    Article  Google Scholar 

  11. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196(6):680–9.

    Article  Google Scholar 

  12. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.

    Article  Google Scholar 

  13. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–87.

    Article  CAS  Google Scholar 

  14. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722.

    Article  Google Scholar 

  15. Okada Y. Pulmonary lymphatic system and lung cancer. 1st ed. Kinpodo; 1989.

    Google Scholar 

  16. Mitaka K, Miyazaki Y, Yasui M, et al. Th2-biased immune responses are important in a murine model of chronic hypersensitivity pneumonitis. Int Arch Allergy Immunol. 2011;154(3):264–74.

    Article  CAS  Google Scholar 

  17. Webb WR, Muller NL, Naidich DP. High-resolution CT of the lung. 5th ed. Wolters Kluwer; 2014.

    Google Scholar 

  18. Giorgia-Dalpiaz AC. Atlas of diffuse lung diseases: a multidisciplinary approach. Springer; 2016.

    Google Scholar 

  19. Kumar R, Spalgais S, Ranga V. Hypersensitivity pneumonitis: clinical, radiological and pathological profile of 103 patients from North India. Monaldi Arch Chest Dis. 2020;90(3):1307.

    Article  Google Scholar 

  20. Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS ONE. 2014;9(2):e86716.

    Article  Google Scholar 

  21. Iftikhar IH, Alghothani L, Sardi A, Berkowitz D, Musani AI. Transbronchial lung cryobiopsy and video-assisted thoracoscopic lung biopsy in the diagnosis of diffuse parenchymal lung disease. A meta-analysis of diagnostic test accuracy. Ann Am Thorac Soc. 2017;14(7):1197–211.

    PubMed  Google Scholar 

  22. Lentz RJ, Argento AC, Colby TV, Rickman OB, Maldonado F. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis. 2017;9(7):2186–203.

    Article  Google Scholar 

  23. Hetzel J, Maldonado F, Ravaglia C, et al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsy working group on safety and utility and a call for standardization of the procedure. Respiration. 2018;95(3):188–200.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Toshihiro Misumi, PhD who supported the statistical analysis.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama City, Kanagawa, 236-0051, Japan

    Hiroko Okabayashi, Tsuneyuki Oda, Hideya Kitamura, Tomohisa Baba & Takashi Ogura

  2. Department of Radiology, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama City, Kanagawa, 236-0051, Japan

    Taiki Fukuda & Tae Iwasawa

  3. Department of Pathology, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama City, Kanagawa, 236-0051, Japan

    Tamiko Takemura

  4. Department of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City, Kumamoto, 860-8556, Japan

    Hiroko Okabayashi & Takuro Sakagami

  5. Department of Radiology, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, 105-8471, Japan

    Taiki Fukuda

Authors
  1. Hiroko Okabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taiki Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tae Iwasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsuneyuki Oda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hideya Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomohisa Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tamiko Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takuro Sakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takashi Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HO takes responsibility for the content of the manuscript, including the integrity of the data and data analysis. DF and TI was involved in the analysis and interpretation of the HRCT findings. TT was involved in the analysis and interpretation of the pathological findings. HO, TI, TsuO, HK, TB, and TaO were involved in the analysis and interpretation of the clinical data. HO, DF, TI, TsuO, HK, TB, TT, TS, and TaO were involved in revising the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hiroko Okabayashi.

Ethics declarations

Ethics approval and consent to participate

This study protocol was reviewed and approved by the Institutional Review Board of Kanagawa Cardiovascular and Respiratory Center, approval number KCRC-20-0023. Consent to participate statement: Because this study was a retrospective study, written informed consent was not obtained from participants. The opt-out consent was adopted for patient enrollment in this study (approved by the Institutional Review Board of Kanagawa Cardiovascular and Respiratory Center).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okabayashi, H., Fukuda, T., Iwasawa, T. et al. The new useful high-resolution computed tomography finding for diagnosing fibrotic hypersensitivity pneumonitis: “hexagonal pattern”: a single-center retrospective study. BMC Pulm Med 22, 76 (2022). https://doi.org/10.1186/s12890-022-01869-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-022-01869-4

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us